Celgene, which has operated a biopharmaceutical manufacturing plant in Phoenix for nearly a decade, has been acquired by Bristol-Myers Squibb for about $74 billion, a merger that creates a global biopharma company with a focus on patients with cancer, inflammatory and immunologic disease, and cardiovascular disease.

The combined company will have nine products with more than $1 billion in annual sales and six expected near-term product launches that provides promise for patients and more than $15 billion in potential revenue, according to the Jan. 3 press release. The release also cites an early-stage pipeline of 50 high-potential assets and expertise in small molecule design, biologics/synthetic biologics, protein homeostasis, antibody engineering, and cell therapy.

New York-based Bristol-Myers Squibb and New Jersey-based Celgene did not mention the Phoenix facility in the release.

Also in 2013, the U.S. Food and Drug Administration approved a drug combination of one of Celgene’s leading therapeutics, Abraxane, with gemcitabine for patients with advance pancreatic cancer. Clinical trials of the drug combination were led by Scottsdale Healthcare (now HonorHealth) and the Phoenix-based Translational Genomics Research Institute.